Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FALCON: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT05650229Phase 2Recruiting
- Sponsor
- Pharming Group
- Start
- Dec 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of napazimone in primary mitochondrial disease (PMD), sponsored by Pharming Group. Started Dec 2022; status: recruiting.
02
Drugs
napazimone
03
Conditions
primary mitochondrial disease (PMD)
Beyond the preview
Go deeper on NCT05650229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650229.